Yin J, Li J, Wang H
Discov Oncol. 2025; 16(1):308.
PMID: 40072658
PMC: 11904034.
DOI: 10.1007/s12672-025-02053-w.
Li D, Liu Y, Lan R, Pillarisetty V, Zhang X, Liu Y
Virchows Arch. 2025; .
PMID: 40014118
DOI: 10.1007/s00428-025-04056-y.
Tieranu C, Balaban D, Tabacelia D, Klimko A, Gheorghe C, Pereira S
Diagnostics (Basel). 2025; 15(4).
PMID: 40002589
PMC: 11854302.
DOI: 10.3390/diagnostics15040437.
Chan A, Zhao Y, Tan H, Chua D, Ng K, Lee S
Ann Surg Oncol. 2025; .
PMID: 39987384
DOI: 10.1245/s10434-024-16674-y.
Stoop T, Seelen L, van t Land F, van der Hout A, Scheepens J, Ali M
BMC Cancer. 2025; 25(1):299.
PMID: 39972248
PMC: 11841322.
DOI: 10.1186/s12885-025-13554-w.
Comprehensive landscape and oncogenic role of extrachromosomal circular DNA in malignant biliary strictures.
Cheng Z, Luo X, Liu W, Lu X, Chang H, Wang Y
Cell Biosci. 2025; 15(1):16.
PMID: 39920810
PMC: 11804034.
DOI: 10.1186/s13578-025-01361-6.
Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Retrospective Cohort Study.
Yamane K, Anazawa T, Nagai K, Kasai Y, Masui T, Izuwa A
Ann Surg Oncol. 2025; .
PMID: 39893341
DOI: 10.1245/s10434-025-16956-z.
ASO Author Reflections: Complete Pathological Response after Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinomas-Curative Surgery in Cured Patients?.
Addeo P, Muzzolini M, Laurent C, Heyd B, Sauvanet A, Garnier J
Ann Surg Oncol. 2025; 32(4):2861-2863.
PMID: 39893336
DOI: 10.1245/s10434-025-16925-6.
Millimeter-scale radioluminescent power for electronic sensors.
Kandala A, Wang S, Blecha J, Wang Y, Lall R, Niknejad A
iScience. 2025; 28(1):111686.
PMID: 39877069
PMC: 11772980.
DOI: 10.1016/j.isci.2024.111686.
Multimodal treatment combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy and adjuvant therapy for pancreatic neck-body cancer: Case series.
Li J, Wang X, Wang Y, Chen K, Li G, Long Y
World J Gastrointest Surg. 2025; 17(1):97897.
PMID: 39872794
PMC: 11757209.
DOI: 10.4240/wjgs.v17.i1.97897.
Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors.
Liu R, Zhou J, Chen X, Zhang J, Chen Q, Liu X
Biomedicines. 2025; 13(1).
PMID: 39857631
PMC: 11762367.
DOI: 10.3390/biomedicines13010047.
HIF-1α expression is associated with the pathological response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients and can be predicted using CECT features.
Wang F, Fan J, Lu F, Xu J, Zhang H, Han J
Quant Imaging Med Surg. 2025; 15(1):662-675.
PMID: 39839013
PMC: 11744163.
DOI: 10.21037/qims-24-103.
Value of [F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy.
Zhang Y, Xu M, Wang Y, Yu F, Chen X, Wang G
Eur J Nucl Med Mol Imaging. 2025; .
PMID: 39820598
DOI: 10.1007/s00259-025-07084-7.
Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer.
Yun W, Chae Y, Han Y, Jung H, Cho Y, Kang H
Ann Surg Oncol. 2025; 32(4):2819-2829.
PMID: 39808212
PMC: 11882644.
DOI: 10.1245/s10434-024-16743-2.
Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study.
Addeo P, Muzzolini M, Laurent C, Heyd B, Sauvanet A, Garnier J
Ann Surg Oncol. 2025; 32(4):2809-2818.
PMID: 39777595
DOI: 10.1245/s10434-024-16735-2.
Metabolic plasticity in pancreatic cancer: The mitochondrial connection.
Ghiglione N, Abbo D, Bushunova A, Costamagna A, Porporato P, Martini M
Mol Metab. 2024; 92:102089.
PMID: 39736443
PMC: 11846432.
DOI: 10.1016/j.molmet.2024.102089.
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Cloyd J, Sarna A, Arango M, Bates S, Bhutani M, Bloomston M
JAMA Surg. 2024; 160(2):172-180.
PMID: 39630427
PMC: 11618571.
DOI: 10.1001/jamasurg.2024.5191.
Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer.
Min J, Yu J, Kim S, Kim Y, Kim K, Park H
J Cachexia Sarcopenia Muscle. 2024; 16(1):e16343.
PMID: 39578950
PMC: 11670158.
DOI: 10.1002/jcsm.13643.
Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma.
Shin K, Yoon M, Kim J, Jang W, Leem G, Jo J
Cancer Med. 2024; 13(22):e70363.
PMID: 39552022
PMC: 11570550.
DOI: 10.1002/cam4.70363.
Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer.
Amrutkar M, Guttorm S, Finstadsveen A, Labori K, Eide L, Rootwelt H
Mol Oncol. 2024; 19(2):391-411.
PMID: 39545923
PMC: 11793008.
DOI: 10.1002/1878-0261.13759.